NCT02973789 2026-03-18
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
NovoCure Ltd.
Phase 3 Completed
Clinical Trials
325 trialsNCT03221426 2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07435311 2026-02-27
A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
R-Pharm
Phase 1 Completed
NCT04024462 2026-02-20
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT03338790 2026-01-27
CheckMate 9KD
Bristol-Myers Squibb
Phase 2 Completed
NCT03474107 2026-01-09
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
Astellas Pharma Inc
Phase 3 Completed
NCT02998528 2026-01-06
CheckMate 816
Bristol-Myers Squibb
Phase 3 Completed
NCT06029127 2026-01-05
A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
BeOne Medicines
Phase 2 Completed
NCT04447118 2025-12-19
PYRAMID-1
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT04034095 2025-12-15
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan
Janssen Pharmaceutical K.K.
Completed
NCT03337698 2025-12-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2 Completed
NCT03595059 2025-12-10
A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
AbbVie
Phase 1 Completed
NCT04428151 2025-12-04
LEAP-009
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT01358877 2025-11-28
APHINITY
Hoffmann-La Roche
Phase 3 Completed
NCT05383482 2025-11-17
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Laekna Limited
Phase 1/2 Completed
NCT03906071 2025-10-21
SAPPHIRE
Mirati Therapeutics Inc.
Phase 3 Completed
NCT05446870 2025-10-01
MK-4830-002
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00532155 2025-09-10
VITAL
Sanofi
Phase 3 Completed
NCT03588091 2025-08-22
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT04666129 2025-08-17
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04527991 2025-08-03
TROPiCS-04
Gilead Sciences
Phase 3 Completed
NCT04306900 2025-07-29
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Trishula Therapeutics, Inc.
Phase 1 Completed
NCT04381832 2025-07-22
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Arcus Biosciences, Inc.
Phase 1/2 Completed
NCT03834506 2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05005728 2025-07-17
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
Phase 2 Completed
NCT03739710 2025-06-15
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
GlaxoSmithKline
Phase 2 Completed
NCT04100018 2025-06-12
CheckMate 7DX
Bristol-Myers Squibb
Phase 3 Completed
NCT02288247 2025-04-08
PRESIDE
Astellas Pharma Inc
Phase 3 Completed
NCT04364620 2025-04-06
AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)
Alethia Biotherapeutics
Phase 2 Completed
NCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT00667251 2025-03-21
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT04256707 2025-03-19
SPRINT
Karyopharm Therapeutics Inc
Phase 1/2 Completed
NCT04880863 2025-03-03
NT-NAP-102-1
NeoTX Therapeutics Ltd.
Phase 2 Completed
NCT02300298 2025-02-11
Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy
Boehringer Ingelheim
Phase 1 Completed
NCT03358875 2025-02-10
RATIONALE-303
BeiGene
Phase 3 Completed
NCT01828112 2025-02-07
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Novartis
Phase 3 Completed
NCT02723955 2024-12-27
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
GlaxoSmithKline
Phase 1 Completed
NCT04276493 2024-12-06
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
BeiGene
Phase 1/2 Completed
NCT03328364 2024-11-21
A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden
Astellas Pharma Inc
Completed
NCT02613507 2024-11-19
CheckMate 078
Bristol-Myers Squibb
Phase 3 Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT03013504 2024-11-06
TROIKA
Prestige Biopharma Limited
Phase 3 Completed
NCT03430843 2024-10-26
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene
Phase 3 Completed
NCT06498921 2024-10-24
BELBEQA
Bayer
Completed
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT02358473 2024-09-19
Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT02864394 2024-09-19
MK-3475-033
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04187898 2024-09-19
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer
Spectrum Pharmaceuticals, Inc
Phase 1 Completed